Prospective Study
Copyright ©The Author(s) 2021.
World J Gastroenterol. Jun 21, 2021; 27(23): 3396-3412
Published online Jun 21, 2021. doi: 10.3748/wjg.v27.i23.3396
Figure 1
Open in New Tab Full Size Figure Download Figure
Figure 1 Patient disposition for Crohn’s disease patients and ulcerative colitis patients. UC: Ulcerative colitis; CD: Crohn’s disease.
Figure 2
Open in New Tab Full Size Figure Download Figure
Figure 2 Proportion (%) of Crohn’s disease and ulcerative colitis patients who maintained or initiated new inflammatory bowel disease drugs at the index date. UC: Ulcerative colitis; CD: Crohn’s disease.
Figure 3
Open in New Tab Full Size Figure Download Figure
Figure 3 Proportion of patients by prescribed inflammatory bowel disease treatment classes during the prospective phase and grouped by trimester for Crohn’s disease (A) and ulcerative colitis patients (B) with at least one treatment. 5-ASA: 5-aminosalicylate.
Figure 4
Open in New Tab Full Size Figure Download Figure
Figure 4  Probability of staying in active disease over 12 mo in Crohn’s disease (A) and ulcerative colitis (B) patients.
  • Citation: Sassaki LY, Miszputen SJ, Kaiser Junior RL, Catapani WR, Bafutto M, Scotton AS, Zaltman C, Baima JP, Ramos HS, Faria MAG, Gonçalves CD, Guimaraes IM, Flores C, Amarante HMBS, Nones RB, Parente JML, Lima MM, Chebli JM, Ferrari MLA, Campos JF, Sanna MGP, Ramos O, Parra RS, da Rocha JJR, Feres O, Feitosa MR, Caratin RF, Senra JT, Santana GO. Real-world treatment patterns and disease control over one year in patients with inflammatory bowel disease in Brazil. World J Gastroenterol 2021; 27(23): 3396-3412
  • URL: https://www.wjgnet.com/1007-9327/full/v27/i23/3396.htm
  • DOI: https://dx.doi.org/10.3748/wjg.v27.i23.3396